Mankind Pharma IPO GMP History
Mankind Pharma IPO has been listed on May 9, 2023 at a listing price of ₹1300, against the issue price of ₹1080 — a gain of ₹220 (+20.37%). The GMP peaked at ₹100 on 15 April 2023 and reached a low of ₹45 on 27 April 2023. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Mankind Pharma IPO raised ₹4326.36 Cr. through its IPO at a price band of ₹1026 to ₹1080 per share, with a lot size of 13 shares. The IPO was open for subscription from 25 Apr 2023 to 27 Apr 2023.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 10 Nov, 11:47 AM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 08 May 2023 | ₹ 90 | ▲ | 8% | — | — |
| 06 May 2023 | ₹ 85 | — | 8% | — | — |
| 05 May 2023 | ₹ 85 | ▲ | 8% | — | — |
| 04 May 2023 | ₹ 80 | ▲ | 7% | — | — |
| 03 May 2023 | ₹ 70 | ▼ | 6% | — | — |
| 02 May 2023 | ₹ 75 | ▲ | 7% | — | — |
| 29 Apr 2023 | ₹ 70 | ▲ | 6% | — | — |
| 28 Apr 2023 | ₹ 55 | ▲ | 5% | — | — |
| 27 Apr 2023 | ₹ 45 | ▼ | 4% | — | — |
| 26 Apr 2023 | ₹ 70 | ▼ | 6% | — | — |
| 25 Apr 2023 | ₹ 85 | ▲ | 8% | — | — |
| 24 Apr 2023 | ₹ 75 | ▼ | 7% | — | — |
| 21 Apr 2023 | ₹ 80 | — | 7% | — | — |
| 20 Apr 2023 | ₹ 80 | ▼ | 7% | — | — |
| 19 Apr 2023 | ₹ 90 | ▲ | 8% | — | — |
| 18 Apr 2023 | ₹ 80 | ▼ | 7% | — | — |
| 17 Apr 2023 | ₹ 90 | ▼ | 8% | — | — |
| 15 Apr 2023 | ₹ 100 | — | 9% | — | — |
Mankind Pharma IPO dates
Key dates from opening to listing. Today is 11 November.
- Open 25 Apr 2023
- Close 27 Apr 2023
- Allotment 03 May 2023
- Refund/credit 04 May 2023
- Listing 09 May 2023
Mankind Pharma IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹1080 |
|---|---|
| GMP-based estimate (pre-listing) | ₹1170 (+8.3%) |
| Listing gain / loss | +₹220 per share |
| Listing date | 09 May, 2023 |
| Actual listing price | ₹1300 (+20.37%) |
Is Mankind Pharma IPO GMP reliable?
Grey market premium for Mankind Pharma IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Mankind Pharma IPO full review for a fundamentals-based assessment before making any grey market trades.
Mankind Pharma IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Mankind Pharma IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Mankind Pharma IPO
Mankind Pharma Limited was incorporated as Mankind Pharma Private Limited at New Delhi on 3 July 1991. As per IQVIA, it is India's fourth largest pharmaceutical company by domestic sales and the third largest by sales volume for MAT December 2022.
It focuses on the Indian market, where it develops, makes and markets formulations across acute and chronic areas such as anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins and respiratory.
In consumer healthcare it has brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin supplements and anti-acne products. Its brands include Manforce, Moxikind-CV, Amlokind-AT, Unwanted-Kit, Prega News, Gudcef and Telmikind.
The IPO was Rs 4,326.36 crore and was entirely an offer for sale by the three individual promoters and investors Cairnhill and Beige, so the company received none of the money.
Frequently asked
What is the GMP of Mankind Pharma IPO?
The current Grey Market Premium (GMP) of Mankind Pharma IPO is ₹ 90.
What is the Kostak Price of Mankind Pharma IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Mankind Pharma IPO is not available.
What is the Subject to Sauda Price of Mankind Pharma IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Mankind Pharma IPO?
Mankind Pharma IPO listed on May 9, 2023 at ₹1300, against the issue price of ₹1080 — a gain of +20.37%.
How did the GMP of Mankind Pharma IPO trend before listing?
The GMP of Mankind Pharma IPO was rising in its final days before listing. The GMP peaked at ₹100 on 15 April 2023. View the day-wise table above for the complete GMP history.
Explore Mankind Pharma IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
